Frazier Lifesciences Acquisition Corporation Stock
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.4 EUR | -10.36% | -0.87% | +73.77% |
May. 16 | Transcript : NewAmsterdam Pharma Company N.V. - Special Call | |
May. 15 | TD Cowen Starts NewAmsterdam Pharma With Buy Rating | MT |
Sales 2024 * | 8.45M 9.16M | Sales 2025 * | 6.3M 6.83M | Capitalization | 1.61B 1.74B |
---|---|---|---|---|---|
Net income 2024 * | -208M -226M | Net income 2025 * | -134M -145M | EV / Sales 2024 * | 190 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 255 x |
P/E ratio 2024 * |
-7.73
x | P/E ratio 2025 * |
-12.4
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.29% |
Latest transcript on Frazier Lifesciences Acquisition Corporation
1 day | -6.81% | ||
1 week | -1.95% | ||
Current month | -12.43% | ||
1 month | -13.14% | ||
3 months | -19.14% | ||
6 months | +90.05% | ||
Current year | +70.99% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-27 | 19.41 | +3.13% | 236 777 |
24-05-29 | 18.98 | -2.22% | 103,242 |
24-05-28 | 19.41 | +3.13% | 236,777 |
24-05-24 | 18.82 | -1.47% | 131,706 |
24-05-23 | 19.1 | -2.45% | 35,045 |
End-of-day quote Nasdaq, May 22, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+70.99% | 1.75B | |
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-1.28% | 21.83B | |
-10.51% | 18.18B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B |
- Stock Market
- Equities
- NAMS Stock